Natural	0	6
history	8	14
of	16	17
colonization	19	30
with	32	35
methicillin	37	47
-	48	48
resistant	49	57
Staphylococcus	59	72
aureus	74	79
(	81	81
MRSA	82	85
)	86	86
and	88	90
vancomycin	92	101
-	102	102
resistant	103	111
Enterococcus	113	124
(	126	126
VRE	127	129
)	130	130
:	131	131
a	133	133
systematic	135	144
review	146	151
.	152	152

No	154	155
published	157	165
systematic	167	176
reviews	178	184
have	186	189
assessed	191	198
the	200	202
natural	204	210
history	212	218
of	220	221
colonization	223	234
with	236	239
methicillin	241	251
-	252	252
resistant	253	261
Staphylococcus	263	276
aureus	278	283
(	285	285
MRSA	286	289
)	290	290
or	292	293
vancomycin	295	304
-	305	305
resistant	306	314
Enterococcus	316	327
(	329	329
VRE	330	332
)	333	333
.	334	334

Time	336	339
to	341	342
clearance	344	352
of	354	355
colonization	357	368
has	370	372
important	374	382
implications	384	395
for	397	399
patient	401	407
care	409	412
and	414	416
infection	418	426
control	428	434
policy	436	441
.	442	442

We	444	445
performed	447	455
parallel	457	464
searches	466	473
in	475	476
OVID	478	481
Medline	483	489
for	491	493
studies	495	501
that	503	506
reported	508	515
the	517	519
time	521	524
to	526	527
documented	529	538
clearance	540	548
of	550	551
MRSA	553	556
and	558	560
VRE	562	564
colonization	566	577
in	579	580
the	582	584
absence	586	592
of	594	595
treatment	597	605
,	606	606
published	608	616
between	618	624
January	626	632
1990	634	637
and	639	641
July	643	646
2012	648	651
.	652	652

For	654	656
MRSA	658	661
,	662	662
we	664	665
screened	667	674
982	676	678
articles	680	687
,	688	688
identified	690	699
16	701	702
eligible	704	711
studies	713	719
(	721	721
13	722	723
observational	725	737
studies	739	745
and	747	749
3	751	751
randomized	753	762
controlled	764	773
trials	775	780
)	781	781
,	782	782
for	784	786
a	788	788
total	790	794
of	796	797
1	799	799
,	800	800
804	801	803
non	805	807
-	808	808
duplicated	809	818
subjects	820	827
.	828	828

For	830	832
VRE	834	836
,	837	837
we	839	840
screened	842	849
284	851	853
articles	855	862
,	863	863
identified	865	874
13	876	877
eligible	879	886
studies	888	894
(	896	896
12	897	898
observational	900	912
studies	914	920
and	922	924
1	926	926
randomized	928	937
controlled	939	948
trial	950	954
)	955	955
,	956	956
for	958	960
a	962	962
total	964	968
of	970	971
1	973	973
,	974	974
936	975	977
non	979	981
-	982	982
duplicated	983	992
subjects	994	1001
.	1002	1002

Studies	1004	1010
reported	1012	1019
varying	1021	1027
definitions	1029	1039
of	1041	1042
clearance	1044	1052
of	1054	1055
colonization	1057	1068
;	1069	1069
no	1071	1072
study	1074	1078
reported	1080	1087
time	1089	1092
of	1094	1095
initial	1097	1103
colonization	1105	1116
.	1117	1117

Studies	1119	1125
varied	1127	1132
in	1134	1135
the	1137	1139
frequency	1141	1149
of	1151	1152
sampling	1154	1161
,	1162	1162
assays	1164	1169
used	1171	1174
for	1176	1178
sampling	1180	1187
,	1188	1188
and	1190	1192
follow	1194	1199
-	1200	1200
up	1201	1202
period	1204	1209
.	1210	1210

The	1212	1214
median	1216	1221
duration	1223	1230
of	1232	1233
total	1235	1239
follow	1241	1246
-	1247	1247
up	1248	1249
was	1251	1253
38	1255	1256
 	1257	1257
weeks	1258	1262
for	1264	1266
MRSA	1268	1271
and	1273	1275
25	1277	1278
 	1279	1279
weeks	1280	1284
for	1286	1288
VRE	1290	1292
.	1293	1293

Based	1295	1299
on	1301	1302
pooled	1304	1309
analyses	1311	1318
,	1319	1319
the	1321	1323
model	1325	1329
-	1330	1330
estimated	1331	1339
median	1341	1346
time	1348	1351
to	1353	1354
clearance	1356	1364
was	1366	1368
88	1370	1371
 	1372	1372
weeks	1373	1377
after	1379	1383
documented	1385	1394
colonization	1396	1407
for	1409	1411
MRSA	1413	1416
-	1417	1417
colonized	1418	1426
patients	1428	1435
and	1437	1439
26	1441	1442
 	1443	1443
weeks	1444	1448
for	1450	1452
VRE	1454	1456
-	1457	1457
colonized	1458	1466
patients	1468	1475
.	1476	1476

In	1478	1479
a	1481	1481
secondary	1483	1491
analysis	1493	1500
,	1501	1501
clearance	1503	1511
rates	1513	1517
for	1519	1521
MRSA	1523	1526
and	1528	1530
VRE	1532	1534
were	1536	1539
compared	1541	1548
by	1550	1551
restricting	1553	1563
the	1565	1567
duration	1569	1576
of	1578	1579
follow	1581	1586
-	1587	1587
up	1588	1589
for	1591	1593
the	1595	1597
MRSA	1599	1602
studies	1604	1610
to	1612	1613
the	1615	1617
maximum	1619	1625
observed	1627	1634
time	1636	1639
point	1641	1645
for	1647	1649
VRE	1651	1653
studies	1655	1661
(	1663	1663
43	1664	1665
 	1666	1666
weeks	1667	1671
)	1672	1672
.	1673	1673

With	1675	1678
this	1680	1683
restriction	1685	1695
,	1696	1696
the	1698	1700
model	1702	1706
-	1707	1707
fitted	1708	1713
median	1715	1720
time	1722	1725
to	1727	1728
documented	1730	1739
clearance	1741	1749
for	1751	1753
MRSA	1755	1758
would	1760	1764
occur	1766	1770
at	1772	1773
41	1775	1776
 	1777	1777
weeks	1778	1782
after	1784	1788
documented	1790	1799
colonization	1801	1812
,	1813	1813
demonstrating	1815	1827
the	1829	1831
sensitivity	1833	1843
of	1845	1846
the	1848	1850
pooled	1852	1857
estimate	1859	1866
to	1868	1869
length	1871	1876
of	1878	1879
study	1881	1885
follow	1887	1892
-	1893	1893
up	1894	1895
.	1896	1896

Few	1898	1900
available	1902	1910
studies	1912	1918
report	1920	1925
the	1927	1929
natural	1931	1937
history	1939	1945
of	1947	1948
MRSA	1950	1953
and	1955	1957
VRE	1959	1961
colonization	1963	1974
.	1975	1975

Lack	1977	1980
of	1982	1983
a	1985	1985
consistent	1987	1996
definition	1998	2007
of	2009	2010
clearance	2012	2020
,	2021	2021
uncertainty	2023	2033
regarding	2035	2043
the	2045	2047
time	2049	2052
of	2054	2055
initial	2057	2063
colonization	2065	2076
,	2077	2077
variation	2079	2087
in	2089	2090
frequency	2092	2100
of	2102	2103
sampling	2105	2112
for	2114	2116
persistent	2118	2127
colonization	2129	2140
,	2141	2141
assays	2143	2148
employed	2150	2157
and	2159	2161
variation	2163	2171
in	2173	2174
duration	2176	2183
of	2185	2186
follow	2188	2193
-	2194	2194
up	2195	2196
are	2198	2200
limitations	2202	2212
of	2214	2215
the	2217	2219
existing	2221	2228
published	2230	2238
literature	2240	2249
.	2250	2250

The	2252	2254
heterogeneity	2256	2268
of	2270	2271
study	2273	2277
characteristics	2279	2293
limits	2295	2300
interpretation	2302	2315
of	2317	2318
pooled	2320	2325
estimates	2327	2335
of	2337	2338
time	2340	2343
to	2345	2346
clearance	2348	2356
,	2357	2357
however	2359	2365
,	2366	2366
studies	2368	2374
included	2376	2383
in	2385	2386
this	2388	2391
review	2393	2398
suggest	2400	2406
an	2408	2409
increase	2411	2418
in	2420	2421
documented	2423	2432
clearance	2434	2442
over	2444	2447
time	2449	2452
,	2453	2453
a	2455	2455
result	2457	2462
which	2464	2468
is	2470	2471
sensitive	2473	2481
to	2483	2484
duration	2486	2493
of	2495	2496
follow	2498	2503
-	2504	2504
up	2505	2506
.	2507	2507
